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Lymphatic Filariasis (LF) is one of the oldest and most
debilitating neglected tropical diseases (NTDs). An esti-
mated 120 million people in 81 countries are infected cur-
rently, and an estimated 1.34 billion live in areas where
filariasis is endemic and are at risk of infection. Approxi-
mately 40 million people suffer from the stigmatizing and
disabling clinical manifestations of the disease, including
15 million who have lymphoedema (elephantiasis) and 25
million men who have urogenital swelling, principally scro-
tal hydrocele1. It is one of the major public health prob-
lems in south-east Asia. Nine of the 11 countries in the
region are known to be endemic for filariasis. More than
60% of the global population and half of the infected cases
are from this region2.
International Task Force for Disease Eradication has
identified LF as one of the seven diseases that can be eradi-
cated3. India is committed to eliminate LF by 20154. To
achieve this goal annual mass drug administration (MDA)
of antifilarial drug was launched in 2004 by the Govern-
ment of India5. According to the guidelines, DEC should
be administered under supervision to all the people ex-
cluding children <2 yr, pregnant women and severely ill
persons (non-eligible)6. In order to achieve the elimina-
tion of LF by 2015 under the National Health Policy,
National Filarial Day (NFD) was proposed to be observed
every year starting from 2004 in the endemic districts4. A
high coverage (>85%) in endemic areas, which is sustained
for 5 years, is required to achieve for the interruption of
transmission and elimination of disease in India6.  Though
reported coverage by health department is high but differ-
ent studies have shown that effective coverage is not that
high7. To achieve and sustain high coverage of drug con-
sumption health education activity is very important8. With
this background, the present study was conducted with
the objective of finding out the coverage and compliance
of MDA in North 24 Parganas district of West Bengal
and community awareness about LF and filariasis elimi-
nation programme.
According to the standard methodology three blocks
and one municipality ward were selected. One block was
selected with >80% coverage, one block with 50–80%
coverage and one block with <50% coverage. In North 24
Parganas district, no block had reported coverage <50%.
Only one block (Bangoan) had reported <80% coverage.
So, that block was selected. All other blocks had reported
>80% coverage. From the list of these blocks, Amdanga
and Haroa blocks were selected. From the selected block
one PHC was randomly selected. From each selected PHC
one subcentre and from each selected subcentre one vil-
lage was selected randomly. From the list of municipali-
ties Khardah Municipality was randomly selected. From
the list of wards of that municipality ward 14 was se-
lected. From each cluster (3 villages and 1 municipal ward)
at least 30 families or 150 persons were surveyed as per
Govt. of India protocol. Mass drug administration was
conducted in May 2010 in North 24 Parganas district.
The survey was conducted immediately after the mass drug
administration. The head of the family or other respon-
sible member present at the time of survey was interviewed
with the help of pre-designed, pre-tested questionnaire. All
the data were compiled and analysed applying appropri-
ate statistical method.
A total of 166 (one from each household) respondents
were interviewed in the district. Majority were females
(72.29%) and mostly (66.87%) in the age group of 18–45
years. In the 166 families out of 807 persons, 778 (96.41%)
were eligible for anti-filarial drugs. Children under two
years, pregnant women and severely ill persons were ex-
cluded. Out of 166 families, 109 families received drugs,
and drug distributor did not visit the other families. In
these 109 families, 46 persons did not receive drugs for
various reasons. Drugs were received by 435 (55.91%)
persons in those 109 families (total eligible 481). Drug
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to fear of side effects or misclassification. In these fami-
lies also, 9.56% persons refused the drug or drug distributor
did not give the drug as they were suffering from various
diseases (Table 1a & b).
In North 24 Parganas, the coverage was found to be
55.91% and compliance was found to be 69.43%. So, ef-
fective coverage (coverage × compliance) was 38.81%.
In rural area, coverage, compliance and effective cover-
age were 72.87, 70.47 and 51.35% respectively. But, in
urban areas, the corresponding figures were 14.22, 56.25
and 8% respectively. The difference between the effective
coverage between rural and urban areas were highly sig-
nificant (z =15.5, p <0.01). Compliance was almost equal
in males and females, 68.72 and 70.19% and difference
was not statistically significant (z = 0.27, p >0.05). In age
wise distribution, compliance was almost similar- and it
was 76.92, 69.70 and 68.81% for 2–5 yr, 6–14 yr and
>15 yr age groups respectively.
 In most of the families (67.88%), ICDS workers were
the drug distributors. Health workers and community vol-
unteers were also involved in drug distribution. In no fam-
ily drug consumption was supervised. Drug was distrib-
uted with the advice to take it in the night after dinner.
Drug was well-tolerated with report of side effect from
only one woman in Piplipara village (Bangoan block). The
woman experienced vomiting within one hour of consump-
tion of drug. She did not consult anybody and it subsided
spontaneously.
Reasons for non-compliance
Even after getting the drug 133 persons (30.57%) did
not consume. The most frequent cause was fear of side
effect (36.84%) followed by inadequate counseling about
the use of the drug for who do not have any clinical mani-
festation of filariasis (27.82%). Other causes of non con-
sumption were no faith on the drug (12.03%), not present
at home (5.26%), etc.
Awareness of the community
Only 55.42% interviewed persons have heard about
LF. Awareness is better in urban ward (88.89%) com-
pared to villages (42.98%). Those who heard about the
name of LF few knew the presenting symptoms. Only
17.36% in rural area and 42.22% in urban area knew at
least one correct presenting symptom of LF. Majority cited
swelling of limb as the presenting symptom. According to
them other presentations were fever, cough, pain, swell-
ing of whole body and itching. Only 13.86% knew the
mode of transmission of filariasis correctly; few had in-
correct knowledge that direct contact, water, and air are
modes of transmission. Only 20% in urban area and 4.13%
respondents in rural area had correct knowledge of mode
of prevention of LF. Very few were aware about treat-
ment of Filariasis and the filaria elimination programme.
Only 8.47% knew about availability of treatment of filari-
asis and 21.08% were aware about filaria elimination
programme. Only 38.04% respondents knew that drug
administration was being done on every house, but they
did not know that it was for elimination of LF. Important
sources of information were Anganwadi worker, Auxil-
iary Nurse Midwife (ANM) and community volunteer. No
IEC activity was reported by any respondent in the fort-
night previous to the drug administration. IEC activity was
conducted only at the time of drug distribution (Table 2).
DEC and Albendazole require to be administered to
>85% of the eligible population in the endemic districts to
achieve the National Health Policy (2002) goal of LF elimi-
nation in India by 20154,6. But in North 24 Parganas dis-
trict, drugs were distributed to 55.91% of the eligible popu-
lation. Only 69.43% of them actually consumed the drug,
making the effective coverage to be 38.81%. In a study
from Andhra Pradesh, compliance was reported to be as
low as 41.96% in Krishna district and highest (76.06%)
in East Gadavari district9. In another study from rural
Puducherry the coverage, compliance and effective cov-
erage rates were 76.2, 88.7 and 67.6% respectively8. In
Table 1a. Person wise distribution of drug ( n=481)
Age group Sex Received Nil Total
(yr) dose
2–5 M 12 (2.50) 4 (0.83) 16 (3.33)
F 14 (2.91) 2 (0.42) 16 (3.33)
6–14 M 30 (6.24) 1 (0.21) 31 (6.45)
F 36 (7.48) 2 (0.42) 38 (7.90)
>15 M 185 (38.46) 17 (3.53) 202 (41.99)
F 158 (32.85) 20 (4.15) 178 (37)
Total 435 (90.44) 46 (9.56) 481 (100)
Figures in parentheses indicate percentages.
Table 1b. Person wise consumption of drug (n=435)
Age group Sex Consumed Nil Total
(yr) dose
2–5 M 10 (2.30) 2 (0.46) 12 (2.76)
F 10 (2.30) 4 (0.92) 14 (3.22)
6–14 M 20 (4.60) 10 (2.30) 30 (6.90)
F 26 (5.98) 10 (2.30) 36 (8.28)
>15 M 126 (28.97) 59 (13.56) 185 (42.53)
F 110 (25.29) 48 (11.03) 158 (36.32)
Total 302 (69.43) 133 (30.57) 435 (100)
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2006, coverage, compliance and effective coverage in
Gujarat were reported to be 85.2, 89 and 75.8% respec-
tively7. A study in Kerala had reported coverage of 77%
and compliance of 39.6% only10. Lahariya and Mishra
had reported coverage ranging from 28.8 to 67.9% in dif-
ferent districts and compliance of 61.3 to 77.4% in Madhya
Pradesh in MDA in 200711. Babu et al12 also reported
low coverage (67.1%) in Orissa. In all these studies there
was wide gap between coverage and compliance. During
MDA round drugs were supposed to be administered un-
der the supervision of the health worker. In the present
study, drug consumption was not supervised. This cre-
ated a room for non-compliance. In the present study, im-
portant causes for non-compliance were fear of side ef-
fects and inadequate counselling. In supervised drug
administration, these non-compliant persons could have
been identified and adequate counselling could have been
done. In Puducherry study also, in 96.57% persons drug
consumption was not supervised8. Supervised drug con-
sumption create an opportunity to increase their aware-
ness about LF and the elimination programme. Drug dis-
tributors did not give the drugs to persons suffering from
various mild diseases. This highlighted the need for proper
training of the drug distributors. Drugs were well-toler-
ated and side effect was negligible. This low level of side
effect might be due to low prevalence of the disease in the
population.
In the present study, awareness of the community about
the disease and the programme was found to be very poor.
Similar low awareness was reported by Eberhard et al13
in an endemic area in Haiti. In a study from Indonesia14,
only 54% have heard the name of filariasis. Mukhopadhyay
et al9 reported that in Andhra Pradesh 65.06% knew the
mode of transmission of LF and 72.93% were aware about
the symptoms of LF. In the present study, very few (8.43%)
were aware about preventive measures and 10.84% for
treatment for LF. Though 38.04% respondents were aware
about MDA, only 21.08% were aware about the purpose
of it, i.e. filaria elimination programme. Babu et al12 re-
ported 96% awareness about LF elimination after the MDA
round. Mukhopadhyay et al9 reported 53.66% awareness
about MDA in Andhra Pradesh.
To improve the situation there is a need for strength-
ening of awareness programme involving both government
health workers and community volunteers. Awareness
progmommes will make the community more receptive and
that will make the elimination goal a reality.
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